268569
Trimethylaluminum solution
2.0 M in hexanes
Synonym(s):
Trimethylalane
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Recommended Products
form
liquid
Quality Level
concentration
2.0 M in hexanes
density
0.683 g/mL at 25 °C
SMILES string
C[Al](C)C
InChI
1S/3CH3.Al/h3*1H3;
InChI key
JLTRXTDYQLMHGR-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
General description
Trimethylaluminum is a Lewis acid having wide applications in organic synthesis. It is employed in organic reactions like cross-coupling reaction, methylenation, carboalumination, cyclopropanation, and rearrangement reactions. Tebbe Reagent (methylenation agent) can be prepared in situ by reacting trimethylaluminum with dichlorobis(cyclopentadienyl)titanium.
Application
Used with 4-bromo-2,6-di-tert-butylphenol (cat. no. 394378) to prepare a wide range of carbonyl compounds via the selective rearrangement of epoxides.
signalword
Danger
Hazard Classifications
Aquatic Chronic 2 - Asp. Tox. 1 - Eye Dam. 1 - Flam. Liq. 2 - Pyr. Liq. 1 - Repr. 2 - Skin Corr. 1B - STOT SE 3 - Water-react 1
target_organs
Central nervous system
supp_hazards
Storage Class
4.2 - Pyrophoric and self-heating hazardous materials
wgk_germany
WGK 3
flash_point_f
-0.4 °F - closed cup
flash_point_c
-18 °C - closed cup
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Tetrahedron, 47, 6983-6983 (1991)
Tetrahedron Letters, 30, 5607-5607 (1989)
Trimethylaluminum
Encyclopedia of Reagents for Organic Synthesis, Second Edition (2007)
Pathology, 47(4), 302-307 (2015-05-06)
BRCA1-associated protein 1 (BAP1) is a tumour suppressor gene frequently inactivated in mesothelioma, rarely also in association with germline mutation. BAP1 mutations have been associated with improved prognosis and distinct clinicopathological features. We sought to determine the clinicopathological significance of
Oncogene, 33(50), 5666-5674 (2013-12-03)
Castration-resistant prostate cancer (CRPC) continues to pose a significant clinical challenge with new generation second-line hormonal therapies affording limited improvement in disease outcome. As the androgen receptor (AR) remains a critical driver in CRPC, understanding the determinants of its transcriptional
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service